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Purpose: The aim of this study was to demonstrate the equivalent efficacy of inhaled
formoterol in asthmatic patients, either given as-needed or on a regular twice-daily schedule.
Methods: Randomised, open 12-week study in patients with mild to moderate asthma not
adequately controlled with inhaled glucocorticosteroids alone. Patients received inhaled
formoterol as needed or on a regular schedule (2 2 puffs/day with 6 mg formoterol per
puff). Patients in the twice-daily formoterol group could use salbutamol as a rescue
medication. The primary endpoint was the number of patients with asthma exacerbations
in each group.
Results: Thirty-nine centres randomised 359 patients. The number of patients with
asthma exacerbations showed neither a clinically relevant nor a statistically significant
difference between groups: formoterol as-needed: 3.95% (7 of 177); twice daily: 3.45%
(6 of 174). Patients in the formoterol as-needed group used significantly less formoterol
(1.5 puffs per day; Po0.0001). Including the saved rescue medication (up to one puff per
day), total beta-2 agonist use in the formoterol as-needed group decreased by
approximately 2–2.5 puffs per day.
Both formoterol treatment schedules were well tolerated. Musculoskeletal pain and
tremor were less frequent in the formoterol as-needed group: headaches were slightly
more frequent.
Conclusion: Formoterol given as needed and without additional beta-2 agonist, and
formoterol given on a regular basis twice daily, supplemented by salbutamol as a rescue
medication, appeared equally effective in this clinical study. Drug consumption was
markedly lower in the former group.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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K. Richter et al.468Introduction MethodsToday, a persistent subacute inflammation is recognised as
the underlying pathological basis of asthma, even in milder
forms. This concept supports the use of anti-inflammatory
therapies as a ‘‘long-term control medication’’.1 For this
reason, the early administration of inhaled glucocorticos-
teroids (GCS) is recommended by international and national
guidelines.2,3
Though inhaled GCS are the mainstay of asthma therapy,
these drugs alone are usually not sufficient. They do not act
rapidly and may take a week or more to improve symptoms
and so are inadequate to adapt therapy to intra- and
between-day variations of asthma severity. Thus, ‘‘quick-
relief medications’’1 inhibiting smooth muscle contraction
supplement GCS therapy. Owing to their efficacy and ease of
administration, rapid-acting inhaled beta-2 agonists have
become the mainstay in this group of therapies. Different
studies have demonstrated the superiority of GCS plus beta-
2 agonist therapy. Price et al.4 and Zetterstro¨m et al.5 found
budesonide plus formoterol more effective than budesonide
alone. Formoterol plus low-dose budesonide was superior
in improving lung function (forced expiratory volume in
the first second; FEV1) compared to the fourfold budesonide
dose without formoterol.6 Similar results were found for
GCS plus other long-acting beta-2 agonist combinations.7,8
Biopsy and lavage data indicate that long-acting beta-2
agonists may possess their own anti-inflammatory
effect.9 Based on such studies, the optimal treatment
for mild to moderate persistent asthma as described by
various guidelines is that of a GCS plus a long-acting beta-2
agonist.
Formoterol (formoterolfumaratdihydrat) is one of the
most widely used selective long-acting beta-2 agonists in
Europe. Formoterol induces bronchodilation within min-
utes10; its effect lasts for at least 12 h, longer than with
most other beta-2 agonists. Its long duration of action
is considered particularly advantageous in nocturnal
asthma.11,12
A recently published study showed that formoterol
given as needed provided better asthma control than
terbutaline, also taken as needed.13 This suggests that
lower formoterol doses than the usual regular dosing
schedule might also provide sufficient asthma control.
Furthermore, a study in patients presenting to the
emergency department with acute severe asthma
showed that the long-acting bronchodilator for-
moterol provided equally rapid improvement of a greater
magnitude and longer duration in lung function than the
short-acting beta-2 agonist salbutamol, without increasing
side effects.14
Thus, we hypothesised that (1) a regular twice-
daily treatment schedule might be substituted by
on-demand treatment and that (2) a short-acting broncho-
dilator might be withheld without impairing patient safety.
Subsequently, we intended to demonstrate that formoterol
given as needed compared to formoterol on a twice-daily
treatment schedule plus a rescue beta-2 agonist was equally
effective in asthmatic patients who continued their cus-
tomary inhaled GCS therapy. The primary efficacy endpoint
was the number of patients with asthma exacerbations in
each group.Patients
Thirty-nine German and Eastern European centres partici-
pated in this study and included male and female out-
patients between 18 and 50 years of age who had a history of
at least 6 months of mild to moderate persistent asthma.
Patients were on inhaled GCS treatment in the last 4 weeks
prior to enrolment, with a stable dose of up to 800 mg
budesonide or equivalent. Mild to moderate asthma was
diagnosed using modified global initiative for asthma (GINA)
criteria2: Patients’ FEV1 was between 60% and 90% of the
predicted value; FEV1 reversibility within 30min of inhaling
two actuations of 100 mg salbutamol had to be X12%, with
an increase of at least 200mL. After the run-in period (see
below) and before randomisation, FEV1 had to be between
50% and 90% of the predicted value, accounting for a
possible worsening of asthma due to changes in GCS and/or
beta-2 agonist therapy during this phase. FEV1 should not
differ more than 15% from the value obtained at the
screening visit. As an indicator for mild to moderate asthma,
patients had to require an average of at least three puffs of
salbutamol a day on at least 5 days during the run-in period,
but not more than twelve puffs on any 1 day. Patients had to
provide written informed consent after having received oral
and written information on the study.
Patients were considered ineligible in the case of
inpatient asthma treatment within 4 weeks prior to the
screening visit, respiratory tract infection within 4 weeks
prior to the screening visit, seasonal asthma during the study
period, treatment with systemic GCS less than 3 months
prior to the screening visit, or a smoking history ofX10 pack
years. During the study, treatment with oral GCS (exceptions
were made for patients requiring intermittent oral GCS
therapy up to 1 week as a result of respiratory infection and
in the case of treatment of asthma exacerbations), sodium
cromoglycate, nedocromil, systemic antihistamines, leuko-
triene antagonists, theophylline or anticholinergic drugs,
beta-receptor blocking drugs, including eye drops was
excluded.Treatment and visits
During a 2-week run-in period, patients received budesonide
according to their previous dose of inhaled GCS up to 800 mg
daily and salbutamol as required, both via Novolizers
(Budecorts 200 Novolizers, Salbu Novolizers, Astellas
Pharma GmbH, formerly Fujisawa Deutschland GmbH).
Afterwards, patients were randomised to one of the
following two groups: (1) formoterol 6.0 mg via Novolizers,
inhalations day by day only as needed, and (2) formoterol
6.0 mg via Novolizers, two inhalations twice daily taken
regularly in the morning and evening, i.e. a daily dosage of
24 mg formoterol.
Patients in the fomoterol as-needed group did not receive
specific instructions on when to use which dose. They were
free to use more than one puff at a time, but they were
informed of the maximum permitted formoterol dosage,
which was 12 puffs per day and a maximum of 6 puffs at a
time.
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(Astellas Pharma GmbH, formerly Fujisawa Deutschland
GmbH). The Novolizers is a refillable, multidose, breath-
actuated dry powder inhaler. In the formoterol Novolizers,
formoterol is bound to the excipient lactose, resulting in an
optimised deposition in the airways. The respirable particle
fraction is on average smaller than 5.5 mm. A cross-over
study with the formoterol Novolizers has shown efficacy and
safety identical to another commercially available formo-
terol dry powder inhaler.15 In patients with moderate to
severe asthma, the ratio of the area under the curve for
FEV1 (AUC012 h) was 1.0170.13 for the 12 mg formulations
(difference not significant).
The treatment period lasted for 12 weeks. All patients
received budesonide delivered by Novolizers at a constant
dose of up to 800 mg daily (Budecorts 200 Novolizers,
Astellas Pharma GmbH, formerly Fujisawa Deutschland
GmbH); this dose had to be identical to the dose during
the run-in period. Patients in the formoterol twice-daily
group received salbutamol via Novolizers as a rescue
medication (Salbu Novolizers, Astellas Pharma GmbH,
formerly Fujisawa Deutschland GmbH). Patients in the
formoterol as-needed group were not permitted to use
salbutamol and had no other rescue medication in addition
to their individual formoterol dose.
On the days of the study visits, the study drugs and any
other asthma medication always had to be taken after lung
function tests in the presence of the investigator.
The study included five patient visits, i.e. screening
(1472 days before baseline), baseline and randomisation
(day 0), and visits after 4, 8 and 12 weeks of therapy (2874,
5674, and 8474 days after the baseline visit). Efficacy and
safety data were determined at all visits.Outcomes
Primary efficacy variable was the number of patients in each
treatment group with an exacerbation of asthma. An
exacerbation was defined as (1) need for treatment with
oral GCS as judged by the investigator or (2) decrease in the
morning peak expiratory flow (PEF) of more than 30% from
the baseline value on two consecutive days. The baseline
PEF value was determined after the run-in period and before
randomisation (day 0). Furthermore, the presence of an
exacerbation was derived from the presence of a corre-
sponding documented adverse event with the MedDRA
lowest level term ‘Exacerbation of asthma’.
Secondary efficacy variables were: (1) time to the first
exacerbation, (2) total number of exacerbations, (3) FEV1,
FEV1% predicted, forced vital capacity (FVC), FEF25–75
(maximum forced expiratory flow of 25–75% of the total
expiratory vital capacity), and PEF by spirometry, (4)
morning/evening PEF, (5) number of inhalations of study
medication (formoterol) per day, (6) number of inhalations
of rescue medication (salbutamol) per day in the formoterol
twice-daily group, (7) evaluation of asthma symptoms
(Asthma Symptom Score; Range: 0–24)—coughing, wheez-
ing, shortness of breath, chest tightness (0–5 rating scales),
nocturnal sleep disturbance (0–4 rating scale), (8) totally
asthma-controlled days, defined as (a) no nocturnal sleep
disturbance and (b) no asthma symptoms during the day and(c) no rescue medication salbutamol, (9) Formoterol-use-
free days in the as-needed treatment arm, and (10)
Investigator’s and patient’s assessments of efficacy on five-
step verbal rating scales.
At each study visit, the investigator measured pulmonary
function by means of spirometry, and recorded FEV1, FVC,
FEF25–75 and PEF. Three readings were performed and the
highest value regarding FEV1 was used for evaluation. The
predicted values were calculated according to the formula
of the ECCS (European Community for Coal and Steel16).
Throughout the study, pulmonary function tests were
performed between approximately 8.00 and 10.00 a.m.
and at approximately the same time points and in the same
position (sitting or standing) for each individual patient. To
avoid bias, patients had to withhold short-acting beta-2
agonists for at least four hours and long-acting beta-2
agonists for at least 12 h prior to each pulmonary function
test.
For PEF at each time point, three readings were obtained;
the best was recorded in the patient’s diary and used for
evaluation.
Safety variables were: (1) adverse events (AE), (2) blood
pressure and heart rate, (3) body weight, and (4) investi-
gator’s and patient’s assessments of tolerability on five-step
verbal rating scales.
Sample size
Sample size was estimated for the primary endpoint, i.e. the
percentage of patients with asthma exacerbations. The
calculation was based on the following assumptions: (1)
independent groups with a size ratio of 1:1 for the as-
needed and the twice-daily treatment group, (2) one-sided
t-test for non-inferiority at a significance level of a ¼ 0:05
and b ¼ 0:20 (power ¼ 80%), (3) expected percentage of
asthma exacerbations in the as-needed and the twice-daily
treatment group ¼ 0.15 (15%), (4) Expected difference
between the as-needed and the twice-daily treatment
group ¼ 0.00 (0%), and (5) irrelevant difference in the
percentage of asthma exacerbations between the two
treatment arms p0.10 (10%).
These assumptions resulted in a sample size of N ¼ 158
evaluable patients per group (NTotal ¼ 316).
Randomisation and blinding
The random plan was drawn up by means of RANCODE
Version 3.6. Randomisation was performed in separate
blocks for each centre. After the run-in period, patients
were randomised in consecutive order.
The investigational product was identical in both treat-
ment arms of the study, but the dosage scheme was
different. Accordingly, a blinding of the two arms was not
possible and the study was performed in an open design.
Statistical methods
The primary efficacy analysis was based on the intention-to-
treat (ITT) population, which included all randomised
patients with at least one regular follow-up visit under
study medication. For the ITT population, missing values of
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carried forward (LOCF), where appropriate. A second
supportive analysis based on the according-to-protocol
(ATP) population, which included all ITT population patients
without major protocol violations. All protocol violations
were assessed by a blinded data review committee, which
decided on exclusions from the ATP analysis. The safety
population, which included all patients who had taken at
least one dose of the study medication formoterol, was used
for safety analyses.
For the statistical analysis, centres with less than two
patients per treatment group were pooled together to an
artificial centre.
As described under Outcomes, the primary efficacy
variable was the number of patients with asthma exacerba-
tions. The analysis was based on the following set of
hypotheses:
H0 : pANXpRT þ 0:10 versus H1 : pANopRT þ 0:10
with (1) pAN: ¼ relative number of patients with asthma
exacerbations in the as-needed treatment arm and (2)
pRT: ¼ relative number of patients with asthma exacerba-
tions in the regular twice-daily treatment arm.
The above hypothesis was tested based on an exact,
unconditional test for binomial differences. In addition, an
exact one-sided 97.5% unconditional confidence interval for
the difference of proportions was calculated. If the upper
limit of this confidence interval was less than 0.10 (or
correspondingly the P-value of the t-test on non-inferiority
was less than 2.5%), then the null hypothesis could be
rejected.
Secondary efficacy variables were analysed descriptively,
with P-values not considered confirmatory. Statistical tests
were chosen as appropriate to the scale of the variable.
The following safety variables were analysed: (1) in-
cidence and frequency of AE, (2) course of vital signs and
body weight, and (3) investigator’s and patient’s assessment
of tolerability. All analyses were explorative.Legal requirements and ethics
The following safety variables were analysed: (1) incidence
and frequency of AE, (2) course of vital signs and body
weight, and (3) investigator’s and patient’s assessment of
tolerability. All analyses were explorative.
The study was submitted to the relevant national
authorities and notified to the local authorities as required
by national laws. It was conducted in accordance with the
ethical principles of the Declaration of Helsinki. The study
documents were reviewed by Independent Ethics Commit-
tees or Institutional Review Boards, which gave positive
opinions prior to the start of the study.Results
Patients
Investigators screened 386 patients, of whom 27 were
screening failures. Thirty-nine centres randomised the
remaining 359 patients to the formoterol as-needed group(n ¼ 182) or to the formoterol twice-daily group (n ¼ 177).
These patients comprise the safety data set.
In the two treatment groups, eight and five patients,
respectively, were withdrawn, so that n ¼ 174 patients in
the formoterol as-needed group and n ¼ 172 patients in the
formoterol twice-daily group completed the study.
Of the 359 patients in the safety data set, five and three
patients, respectively, in the two treatment groups were
withdrawn before the first regular follow-up visit at week 4,
so that the ITT data set comprised n ¼ 351 patients: n ¼ 177
patients in the formoterol as-needed group and n ¼ 174
patients in the formoterol twice-daily group. Relevant
protocol violations occurred in 13 and 6 patients of these
351 patients, so that the ATP data set comprised n ¼ 332
patients: n ¼ 164 patients in the formoterol as-needed
group and n ¼ 168 patients in the formoterol twice-daily
group. The most frequent relevant protocol deviations were
use of inadmissible concomitant medication and inadequate
use of the rescue medication salbutamol. Disposition of
patients and reasons for withdrawal are compiled in Fig. 1.
Demographics and baseline data
Relevant demographic and baseline data for both treat-
ments are compiled in Table 1.
The two treatment groups were well balanced, which was
confirmed by different tests on baseline homogeneity.
Statistical tests revealed significant or near-significant
centre effects for age, height, weight, gender, and FEV1%
predicted at Visit 1, which indicates that patient popula-
tions differed between centres. This diversity increases the
population’s representative character and thus the general
applicability of the study results.
Compliance
For the treatment group receiving formoterol twice daily,
compliance with formoterol intake was calculated as the
total number of study days multiplied by four puffs
compared to the actual number of puffs derived from the
drug accountability data. Mean compliance was high with
95%. Compliance could not be calculated for the group
taking formoterol as needed due to the lack of a reference
value.
Analyses of efficacy—primary efficacy variable
exacerbation of asthma
In the group taking formoterol regularly twice daily, six
patients (3.45%) suffered an exacerbation of asthma; in the
group taking formoterol as needed, these were seven
patients (3.95%; ITT population; Table 2). The null hypoth-
esis of inferiority of the as-needed therapy versus the twice-
daily treatment schedule of formoterol could be rejected
(P ¼ 0:0002). The point estimate of difference (0.51%) as
well as the upper limit of the one-sided 97.5% confidence
interval (N; 4.95%) were below 10%, the pre-specified
border of a clinically irrelevant difference. Thus the as-
needed treatment schedule was non-inferior to the twice-
daily formoterol treatment schedule in preventing asthma
exacerbations.
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Figure 1 Disposition of patients and allocation to analysis populations. ITT: intention to treat; ATP: according to protocol.
Table 1 Baseline data (SD: standard deviation).
Demographic data Treatment
Formoterol as needed Formoterol twice daily
Total N—safety data set 182 177
Sex (N (%))
Male 72 (39.6) 77 (43.5)
Female 110 (60.4) 100 (56.5)
Smoking history (N (%))
Smoker (o10 pack years) 10 (5.5) 8 (4.5)
Non-smoker 148 (81.3) 141 (79.7)
Ex-smoker 24 (13.2) 28 (15.8)
Total N—ITT data set 177 174
Age (years) mean7SD 39.578.7 38.478.4
Height (cm) mean7SD 168.078.5 169.079.1
Weight (kg) mean7SD 73.67714.80 74.60715.76
Body mass index (kg/m2) mean7SD 26.1175.02 26.0274.76
Duration of asthma disease (years) mean7SD 9.178.5 10.079.1
FEV1 (L) at day 0 mean7SD 2.5170.54 2.5770.59
FEV1% predicted at day 0 mean7SD 77.2378.75 76.4978.75
FVC (L) at day 0 mean7SD 3.2470.80 3.3170.79
PEF (L/s) at day 0 mean7SD 5.1671.98 5.1771.81
Reversibility test
Increase of FEV1 over initial value (%) mean7SD 23.5710.3 23.379.4
Randomised trial comparing as-needed versus regular treatment 471Data for the ATP population were similar, with a point
estimate of difference of 0.52% and an upper limit of the
one-sided 97.5% confidence interval of 3.83% (Table 2). The
analyses for both definitions of asthma exacerbation
(according to the number of AE with the applicable MedDRA
term and according to a clinical definition based on a
repeated decrease of PEF or a progressive increase of
asthma symptoms) gave corresponding results.Time to first exacerbation
The mean time to first exacerbation was approximately 1
week longer in the formoterol as-needed group (53.0724.3
days) compared to the formoterol regularly twice-daily
group (46.3712.6 days). This difference was not statisti-
cally significant. No patients suffered from second exacer-
bations.
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Table 2 Exacerbation of asthma based on reported adverse events.
Population Percentage (number) of patients with
asthma exacerbations
Difference (as
needed—twice daily)
One-sided 97.5%
confidence interval
P-value*
Formoterol twice
daily
Formoterol as
needed
ITT 3.45% (6 of 174) 3.95% (7 of 177) 0.51% (N; 4.95%) 0.0002
ATP 3.57% (6 of 168) 3.05% (5 of 164) 0.52% (N; 3.83%) o0.0001
Unconditional exact test for non-inferiority for a binomial difference.
2
3
4
5
6
7
D 0 D 28 D 56 D 84 D 0 D 28 D 56 D 84 D 0 D 28 D 56 D 84
Formoterol as needed Formoterol twice daily
FEV1 [L] FVC [L] PEF [L/s]
Figure 2 FEV1, FVC, and PEF by spirometry—mean + or  SEM (standard error of the mean); highest value; ITT data set.
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Relevant spirometry data are given in Fig. 2. Parameters
increased to a similar extent in both treatment groups until
the last examination (day 84). The extent of improvement
generally corresponded to 10–20% of the mean starting
values. Improvement was somewhat quicker or larger in the
formoterol twice-daily group for FEV1, FVC, and PEF, and in
the formoterol as-needed group for FEF25–75. With the
exception of FVC data on day 56, the differences between
groups were not significant. ITT and ATP analyses gave
compatible results.
In the formoterol as-needed group, mean morning PEF
recordings as self-determined by a pocket peak flow metre
increased gradually from 3667108 L/min in the 2-week run-
in period to 3857108mL/min in Week 9–12, i.e. by 19mL/
min. In the formoterol twice-daily group, the increase was29mL/min and thus larger. The difference between groups
approached statistical significance for the weeks 5–8 and
9–12 data (P ¼ 0:0624 and 0:0562, respectively). Data for
the ATP population were numerically similar, but did not
approach statistical significance. Evening PEF was numeri-
cally mostly higher than morning PEF, and the same trends as
described for morning PEF were observed.Use of formoterol and salbutamol
Patients in the formoterol as-needed group used between 41
and 45 puffs less per 4-week period than patients in the
formoterol twice-daily group (see Table 3), corresponding to
an average of approximately 1.5 saved puffs of formoterol
per day. The difference between groups was highly
significant for all three periods (Po0.0001). Between 7%
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Table 3 Number of formoterol inhalations (SD: standard deviation).
Total number of inhalations of study medication (formoterol) per visit Visit
Weeks 1–4 Weeks 5–8 Weeks 9–12
Formoterol as needed
Mean7SD 70.9745.7 67.5747.0 66.7749.2
N 175 174 172
Formoterol twice daily
Mean7SD 111.978.2 110.5711.7 111.3710.6
N 173 173 171
Randomised trial comparing as-needed versus regular treatment 473and 7.5% of patients in the formoterol as-needed group
required more than four puffs per day, the regular dose in
the formoterol twice-daily group.
Patients in the formoterol twice-daily group needed an
average of 29741 puffs of salbutamol in the first four study
weeks and 17734 puffs in the last four study weeks. This is
an average of 0.60–1.03 puffs per day. Patients in the
formoterol as-needed group were not allowed to take any
puffs of salbutamol.
Adding up the salbutamol dose and the higher use of
formoterol in the formoterol twice-daily group, patients
under this schedule had a higher consumption of beta-2
agonists by an average of 2–2.5 puffs per day.
Asthma symptom score
The mean subscores for wheezing, shortness of breath, chest
tightness, coughing, and sleep disturbance as well as the
mean Total Asthma Symptom Score decreased gradually and
to a comparable extent in both treatment groups (Total
Asthma Symptom Score at study end: formoterol as-needed:
1.4072.43 versus baseline; formoterol twice daily:
1.5672.16 versus baseline).
Asthma-controlled days and formoterol-use-free
days
The mean sum of asthma-controlled days increased steadily
from 0.6 or 0.4 days in the run-in period to an average of
6.679.1 days in the formoterol as-needed group and
10.5711.2 days in the formoterol twice-daily group during
the last four study weeks. The difference between groups
was statistically significant for the two periods weeks 5–8
and 9–12 (Pp0.0005).
The mean number of formoterol-use-free days (only valid
for the as-needed treatment arm) increased from 3.876.8
during weeks 1–4 to 4.778.0 during weeks 5–8 and finally to
5.578.7 during weeks 9–12.
Analysis of efficacy—investigator’s and patient’s
assessment of efficacy
Investigators assessed approximately 90% of the patients as
markedly or moderately improved, the two highest ranks on
the five-step verbal rating scale used. The differencebetween the two groups was not significant. Patients
assessed the efficacy of formoterol twice daily more
favourably than the efficacy of formoterol as needed
(94.2% versus. 85.7% better or much better; 65.1% versus
53.7% much better). This difference between groups was
statistically significant (P ¼ 0.0064).
Analysis of safety
Both formoterol treatment schedules were well tolerated in
this study. Numerically, AE were less frequent (73 versus 84
AE) and less severe (0 versus 3 severe AE; 23 versus 28
moderately severe AE) in the formoterol as-needed group,
and in this group treatment-related AE were also less
frequent (2 versus 6).
The distribution of AE to the different MedDRA System
Organ Classes was generally similar. Musculoskeletal pain
and tremor were less frequent in the formoterol as-needed
group; headaches were slightly more frequent.
Two serious AE occurred during the treatment phase of
the study, both in the formoterol twice-daily group (death
caused by miliary tuberculosis; hospitalisation for serous
otitis; both approximately two months after start of
therapy). Both were unrelated to the formoterol medication
and thus do not indicate an increased risk of the twice-daily
application schedule.
Vital parameters such as body weight, blood pressure and
pulse rate showed neither material change during the study
nor any influence of the treatment schedule.
The overall safety assessment showed no major differ-
ence between treatment schedules. Tolerability was as-
sessed as very good or good by over 96% of investigators and
patients in both groups.
Discussion
In this study, we demonstrate equivalent efficacy with
regard to the primary endpoint asthma exacerbations of a
treatment regimen with formoterol used as needed and a
treatment with formoterol on a twice-daily basis in mild to
moderate persistent asthma. At 3.45–3.95% over 3 months,
the rate of asthma exacerbations we observed was lower
than the 15% anticipated for sample size calculation. Using
comparable definitions of exacerbation, rates corresponding
to approximately 15% over 3 months had previously been
observed by Tattersfield13 and by Pauwels17, both in studies
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Table 4 Number of formoterol-use-free days; weeks
9–12; formoterol as-needed group; ITT population.
Number of formoterol-use-
free days in weeks 9–12
Formoterol as needed
N %
0 106 61.27
1–7 16 9.25
8–14 21 12.14
414 30 17.34
K. Richter et al.474with formoterol and inhaled GCS. However, in these studies
inhaled GCS were not standardised, but used according to
real-life conditions, and no separate rescue beta-2 agonist
was supplied. Our absolute rates are more in line with
findings from the FACET trial,6 where patients received
formoterol twice daily (24mg total daily dose) in addition to
budesonide 100 or 400 mg twice daily (200 or 800 mg total
daily dose). Here, the rate of severe exacerbations—iden-
tical to our definition of an exacerbation—was 19% and 30%,
respectively, over a 12-month period, depending on the
budesonide dose. In our study, the budesonide dose was
approximately 520 mg/day and thus in between the low and
the high dose of the FACET trial. Accordingly, our results still
show a somewhat better control of asthma exacerbations
than the 6.4% expected from the FACET trial, linearly
correcting for GCS dose and study duration.
Our efficacy results for twice-daily formoterol supple-
mented by a rescue medication compare well with the
historical benchmarks. Thus, it is encouraging to find that
formoterol given only as needed and without rescue
medication controlled asthma exacerbations, the primary
efficacy endpoint, to an equivalent extent. The lower than
expected rate of asthma exacerbations reduced the statis-
tical power to verify a correspondingly smaller range of an
irrelevant difference for the primary endpoint. However,
both the point estimate and the upper limit of the 97.5%
confidence interval for differences between groups—below
1% and below 5%, respectively—confirm the clinical equiva-
lence of both dosing schedules.
Asthma symptoms improved to a comparable extent in
both groups, but numerical mostly non-significant differ-
ences between groups in secondary endpoints generally
favoured the twice-daily formoterol schedule. The number
of asthma-controlled days was significantly different be-
tween groups, with a difference of up to four days per four-
week period in favour of the formoterol twice-daily group.
Patients’ subjective efficacy ratings were also significantly
higher for twice-daily formoterol.
Overall, these data indicate that in asthma patients using
regular inhaled GCS (1) formoterol on an individual dosing
schedule is sufficient to avoid severe asthma exacerbations
and (2) patients can be trusted to find this dose. Though we
do not have data on this aspect, differences in secondary
and less severe efficacy endpoints could be explained by
three reasons. First, the availability of two inhalation
devices, containing formoterol and a rescue medication,
might make patients feel more secure than only one device
(with formoterol). From a psychological point of view, this
could result in a more favourable rating of subjective
endpoints in the formoterol twice-daily group. Second,
patients may forget dosing altogether if they are allowed to
deviate from a structured twice-daily application schedule.
Third, patients could prefer to tolerate a certain amount of
less severe asthma symptoms for the benefit of reduced drug
consumption.
Indeed, drug consumption was markedly lower in the
formoterol as-needed group. Adding formoterol and salbu-
tamol puffs, dosing formoterol as needed reduced the total
use of a beta-2 agonist by approximately 2–2.5 puffs per
day: a reduction of 1.5 puffs of formoterol per day plus the
saved salbutamol of approximately 0.6–1.0 puffs per day.
Thus, the amount of drug saved corresponded to nearly halfof the conventional dose of approximately five puffs with
regular twice-daily dosing: two times two puffs of formoter-
ol per day plus up to one puff of a rescue beta-2 agonist.
Reducing the need for beta-2 agonists by almost 50% without
increasing the risk of an asthma exacerbation appears
clearly clinically relevant.
Furthermore, it is interesting to look at the consumption
of beta-2 agonists from the perspective of individual
patients. Whereas the recommended formoterol dosing
schedule is twice daily, whether needed or not, data from
the formoterol as-needed group show that actually more
than 35% of the patients did not require this drug on a daily
schedule at all (see Table 4). An increasing proportion of
patients even did not need formoterol for more than seven
days in subsequent four-week periods. During the first four
study weeks, every fifth patient (19.9%) fell into this
category, and during the last four study weeks this applied
to almost every third patient (29.5%). In the last study
period, every sixth patient (17.3%)—who would usually have
received daily formoterol—required a beta-2 agonist on less
than 50% of the days during this month.
Use of formoterol showed significant treatment-by-centre
interactions at all time points and in both analysis
populations. Thus, contrary to the lower mean use of
formoterol in the formoterol as-needed group, in some
centres the patients in this group obviously used more
formoterol than the patients in the formoterol twice-daily
group. The exact reason for this finding is unknown. It may
reflect patient populations unresponsive to instructions,
who have decided to stick to the usual twice-daily inhalation
schedule. Without a second beta-2 agonist as a rescue
medication, any rescue puffs taken would increase the total
formoterol dose over four puffs per day. Though contrary to
our intentions, such patient behaviour is not critical. Taking
into account the equivalence of both treatment schedules in
the control of asthma exacerbations, it appears safe to offer
patients the as-needed formoterol approach when applying
our results to everyday practice.
When planning the study, we were unsure whether the
open design introduced any bias through patient preference,
and if so, in what direction. Results now give an answer to
this question. Despite a comparable efficacy of both
treatment schedules in the investigators’ assessment of
general efficacy, the patients assessed the regular twice-
daily treatment schedule more favourably. As already
indicated above, this difference might at least partly be
based on a psychological rationale: patients in the for-
moterol as-needed group may have felt less secure with only
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suggest that this subjective shortcoming may be overcome
by intensified patient counselling, including the information
that formoterol is classified by international asthma
initiatives as a rapidly acting drug,2,18 and a second beta-2
agonist is not required to prevent asthma attacks more
efficiently.
Both treatment schedules were well tolerated. Head-
aches, tremor and muscle pains are known side effects of
beta-2 agonists. It seems plausible that a reduction of the
dose, such as was seen in the formoterol as-needed group
reduces tremor and muscle pains. There is no obvious reason
for the minor increase of headache frequency in the
formoterol as-needed group; withdrawal effects stimulated
by an extension of the dosing interval are previously
unreported.
It is a clinical reality that many patients prescribed a fixed
dosing schedule use a beta-2 agonist only as needed. Our
study showed that this is acceptable. We found no
difference in the incidence of severe asthma attacks. A
fixed dosing schedule and the availability of a second—
short-acting—beta-2 agonist may control less severe symp-
toms better, but the difference is of marginal clinical
relevance and appears well balanced by the amount of beta-
2 agonist saved with the as-needed approach. Furthermore,
this study is a point in favour of individual versus fixed
combination drugs including a beta-2 agonist. Fixed combi-
nation drugs do not allow an individual step-up or step-down
of either component and thus forego the possibilities for
major reductions of drug exposure, which may, like in our
study, range up to 50%.
When prescribing long-acting beta-2 agonists in an as-
needed schedule, patients should be instructed that this
approach does not apply to their inhaled GCS. In the light of
recent findings on their safety, regular therapy with GCS
should always accompany the long-term use of long-acting
beta-2 agonists.18,19
As a conclusion and based on a comparable efficacy in
preventing asthma exacerbations and a markedly lower drug
consumption compared to a regular twice-daily formoterol
application schedule, dosing formoterol (Formotops Novo-
lizers, Astellas Pharma GmbH, formerly Fujisawa Deutsch-
land GmbH) only as needed possesses a positive benefit-risk
profile. Due to its multicentre design and the inclusion of a
diverse patient population, the results of this study are
representative and applicable to a general population with
mild to moderate asthma.
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